Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal

Therapeutic Drug Monitoring

Volumn 28, Issue 6, 2006, Pages 784-792

  Roberts, Darren M ^a,b,c   Southcott, Emma ^d   Potter, Julia M ^b,d   Roberts, Michael S ^e   Eddleston, Michael ^a,c,f   Buckley, Nick A ^a,b,c  

^a South Asian Clinical Toxicology Research Collaboration   (Australia)

^b The Australian National University   (Australia)

^c UNIVERSITY OF COLOMBO   (Sri Lanka)

^d CANBERRA HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Activated charcoal; Oleander; Pharmacokinetic; Poisoning; Thevetia

Indexed keywords

ACTIVATED CARBON; ATROPINE; CARDENOLIDE; CHARCOAL; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT;

ABSORPTION; ADOLESCENT; ADULT; AREA UNDER THE CURVE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOASSAY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; PLANT INTOXICATION; PLANT SEED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF POISONING; SINGLE DRUG DOSE; THEVETIA; THEVETIA PERUVIANA; TOXICOKINETICS; TREATMENT OUTCOME;

ABSORPTION; ADOLESCENT; ADULT; CARDENOLIDES; CHARCOAL; CROSS REACTIONS; DIGOXIN; FEMALE; HALF-LIFE; HUMANS; MALE; THEVETIA;

EID: 33845714372     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31802bfd69     Document Type: Conference Paper

References (53)

1. Langford SD, Boor PJ. Oleander toxicity: an examination of the human and animal toxic exposures. Toxicology. 1996;109:1-13.
2. Saravanapavananthan N, Ganeshamoorthy J. Yellow oleander poisoning: a study of 170 cases. Forensic Sci Int. 1988;36:247-50.
3. Saraswat DK, Garg PK, Saraswat M. Rare poisoning with cerebra thevetia (yellow oleander): review of 13 cases of suicide attempt. J Assoc Phys India. 1992;40:628-629.
4. Bose TK, Basu RK, Biswas B, et al. Cardiovascular effects of yellow oleander ingestion. J Indian Med Assoc. 1999;97:407-410.
5. Eddleston M, Ariaratnam CA, Meyer WP, et al. Epidemic of self-poisoning with seeds of the yellow oleander tree (Thevetia peruviana) in northern Sri Lanka. Trop Med Int Health. 1999;4:266-273.
6. Roberts DM, Eddleston M. Yellow oleander poisoning. In: Nayyar V, ed. Critical Care Update 2004. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2005:189-200.
7. Radford DJ, Gillies AD, Hinds JA, et al. Naturally occurring cardiac glycosides. Med J Aust. 1986;144:540-544.
8. Rao EV. Cardiac glycosides of Thevetia peruviana and Cerbera odollam. Indian J Pharm. 1973;35:107-113.
9. Kyerematen G, Hagos M, Weeratunga G, et al. The cardiac glycosides of Thevetia ovata A.DC. and Thevetia nereifolia Juss. ex Stend. Acta Pharm Suec. 1985;22:37-44.
10. Middleton WS, Chen KK. Clinical results from oral administration of thevetin, a cardiac glycoside. Am Heart J. 1936;11:75-88.
11. Bhatia ML, Manchanda SC, Roy SB. Haemodynamic studies of peruvoside in human congestive failure. BMJ. 1970;3:740-743.
12. Arora RB, Sharma JN, Bhatia ML. Pharmacologic evaluation of peruvoside, a new cardiac glycoside from Thevetia neriifolia with a note on its clinical trials in patients with congestive heart failure. Indian J Exp Biol. 1967;5:31-36.
13. Arnold HL, Middleton S, Chen KK. The action of thevetin, a cardiac glucoside, and its clinical application. Am J Med Sci. 1935;189:193-206.
14. Schwind K. Bericht über die klinische prüfung von peruvosid [Report on the clinical testing of peruvoside]. Medizinische Welt. 1969;3:134-142.
15. Frölich JC, Falkner FC, Watson JT, et al. Metabolism of peruvoside in man. Eur J Clin Pharmacol. 1972;5:65-71.
16. 3 peruvosid]. Klin Wochenschr. 1969;47:1157-1166.
17. 3-digitoxin in guinea pigs]. Arzneimittelforschung. 1968;18:1597-1601.
18. Forth W, Fubukawa E, Rummel W. Intestinale resorption von herzglykosiden in vitro und in vivo [Intestinal absorption of cardiac glycosides in vitro and in vivo]. Naunyn Schmiedebergs Arch Pharmak Exp Path. 1969;262:53-72.
19. Lalonde RL, Deshpande R, Hamilton PP, et al. Acceleration of digoxin clearance by activated charcoal. Clin Pharmacol Ther. 1985;37:367-371.
20. Reissell P, Manninen V. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin: evidence for intestinal secretion of glycosides. Acta Med Scand Suppl. 1982;668:88-90.
21. Caldwell JH, Caldwell PB, Murphy JW, et al. Intestinal secretion of digoxin in the rat. Augmentation by feeding activated charcoal. Naunyn Schmiedebergs Arch Pharmacol. 1980;312:271-275.
22. Park GD, Goldberg MJ, Spector R, et al. The effects of activated charcoal on digoxin and digitoxin clearance. Drug Intell Clin Pharm. 1985;19:937-941.
23. Ibanez C, Carcas AJ, Frias J, et al. Activated charcoal increases digoxin elimination in patients. Int J Cardiol. 1995;48:27-30.
24. Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet. 2000;355:967-972.
25. de Silva HA, Fonseka MMD, Pathmeswaran A, et al. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet. 2003;361:1935-1938.
26. Eddleston M, Juszczak E, Buckley NA, et al. Randomised controlled trial of routine single or multiple dose superactivated charcoal for self-poisoning in a region with high mortality. Clin Toxicol. 2005;43:442-443.
27. Juurlink DN, Sivilotti MLA. Multidose activated charcoal for yellow oleander poisoning. Lancet. 2003;362:581.
28. Cheung K, Hinds JA, Duffy P. Detection of poisoning by plant-origin cardiac glycosides with the Abbott TDx analyser. Clin Chem. 1989;35:295-297.
29. Hoffman RS. Non-pharmacological cardioactive steroids. J Toxicol Clin Toxicol. 2002;40:285-286.
30. Uber-Bucek E, Hamon M, Pham Huy C, et al. Determination of thevetin B in serum by fluorescence polarization immunoassay. J Pharm Biomed Anal. 1992;10:413-419.
31. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 2nd ed. Philadelphia: Lea & Febiger; 1989.
32. Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm. 1988;16:475-492.
33. Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in biological activity of digoxin from four preparations. N Engl J Med. 1971;285:1344-1347.
34. Jounela AJ, Pentikäinen PJ, Sothmann A. Effect of particle size on the bioavailability of digoxin. Eur J Clin Pharmacol. 1975;8:365-370.
35. Modell W, Kwit NT, Dayrit C, et al. Thevetin, a cardiac glycoside with an unusual speed of action in man. J Pharmacol Exp Ther. 1948;94:44-52.
36. Kohli JD, Vohra MM. Pharmacological studies on peruvoside: a new cardiac glycoside from Thevetia peruviana Juss. Arch Int Pharmacodyn. 1960;126:412-425.
37. Green R, Sitar DS, Tenenbein M. Effect of anticholinergic drugs on the efficacy of activated charcoal. J Toxicol Clin Toxicol. 2004;42:267-272.
38. Bennett PN, Davies DS, Hawksworth GM. In vivo absorption studies with paraquat and diquat in the dog. Br J Pharmacol. 1976;58:284P.
39. Rashid MU, Bateman DN. Effect of atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. Br J Clin Pharmacol. 1990;30:25-34.
40. Rivera-Calimlim. Problems of therapeutic drug monitoring of chlorpromazine. Ther Drug Monitor. 1982;4:41-49.
41. Consolo S, Morselli PL, Zaccala M, et al. Delayed absorption of phenylbutazone caused by desmethyl imipramine in humans. Eur J Clin Pharmacol. 1970;10:239-242.
42. Nimmo J, Heading RC, Tothill P, et al. Pharmacological modification of gastric emptying: effects of propantheline and metoclopramide on paracetamol absorption. Br Med J. 1973;1:587-589.
43. Morgan JP, Nathan G, Rivera-Calimlim L, et al. Imipramine caused interference with levodopa absorption from the gastrointestinal tract in rats. J Pharmacol Exp Ther. 1975;192:451-457.
44. Chopra RN, Mukerjee B. The pharmacological action of 'Thevetin': a glucoside occurring in Thevetia neriifolia (yellow oleander). Indian J Med Res. 1933;20:903-912.
45. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol. 1999;37:731-751.
46. Chen KK, Chen AL. The action of crystalline thevetin, a cardiac glucoside of Thevetia neriifolia. J Pharm Exp Ther. 1934;51:23-34.
47. Chyka PA, Seger D, Krenzelok EP, et al. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. Clin Toxicol. 2005;43:61-87.
48. Lohmöller G, Lydtin H. Mechanocardiographische untersuchungen über die wirkung von peruvosid auf das suffiziente menschliche herz [Mechano cardiographic studies on the effect of peruvoside on the normal human heart]. Arzneimittel-Forschung (Drug Res). 1971;21:1567-1571.
49. Chemical Abstracts Service. SciFinder Scholar. Columbus, OH; 2006.
50. 3 in human subjects. J Pharmacol Exp Ther. 1964;145:351-356.
51. Micromedex® Healthcare Series. Greenwood Village, CO: Micromedex; 2006.
52. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals. 12th ed. Whitehouse Station, NJ: Merck & Co.; 1996.
53. Caldwell JH, Bush CA, Greenberger NJ. Interruption of the enterohepatic circulation of digitoxin by cholestyramine: II. Effect on metabolic disposition of tritium-labelled digitoxin and cardiac systolic intervals in man. J Clin Invest. 1971;50:2638-2644.